190 related articles for article (PubMed ID: 34894110)
21. Relationship of cognitive impairment with depressive symptoms and psychosocial function in patients with major depressive disorder: Cross-sectional analysis of baseline data from PERFORM-J.
Sumiyoshi T; Watanabe K; Noto S; Sakamoto S; Moriguchi Y; Tan KHX; Hammer-Helmich L; Fernandez J
J Affect Disord; 2019 Nov; 258():172-178. PubMed ID: 31426015
[TBL] [Abstract][Full Text] [Related]
22. Canadian economic impact of improved workplace productivity in patients with major depressive disorder treated with vortioxetine.
Lachaine J; Beauchemin C; Bibeau J; Patenaude J; Chokka P; Proulx J; Bougie J
CNS Spectr; 2020 Jun; 25(3):372-379. PubMed ID: 31120009
[TBL] [Abstract][Full Text] [Related]
23. Vortioxetine Versus Placebo for Major Depressive Disorder: A Comprehensive Analysis of the Clinical Trial Dataset.
Iovieno N; Papakostas GI; Feeney A; Fava M; Mathew SJ; Iosifescu DI; Murrough JW; Macaluso M; Hock RS; Jha MK
J Clin Psychiatry; 2021 Jun; 82(4):. PubMed ID: 34133089
[No Abstract] [Full Text] [Related]
24. Vortioxetine: A Review in Cognitive Dysfunction in Depression.
Frampton JE
Drugs; 2016 Nov; 76(17):1675-1682. PubMed ID: 27807822
[TBL] [Abstract][Full Text] [Related]
25. The effectiveness of vortioxetine on neurobiochemical metabolites and cognitive of major depressive disorders patients: A 8-week follow-up study.
Zhang Y; Lai S; Zhang J; Wang Y; Zhao H; He J; Huang D; Chen G; Qi Z; Chen P; Yan S; Huang X; Lu X; Zhong S; Jia Y
J Affect Disord; 2024 Apr; 351():799-807. PubMed ID: 38311073
[TBL] [Abstract][Full Text] [Related]
26. Effectiveness and Safety of Vortioxetine for the Treatment of Major Depressive Disorder in the Real World: A Systematic Review and Meta-Analysis.
Li Z; Liu S; Wu Q; Li J; Yang Q; Wang X; Peng P; Wang Q; Liu Y; Li M; Hao Y; Xu H; He L; Wang Y; Chen S; Liu T
Int J Neuropsychopharmacol; 2023 Jun; 26(6):373-384. PubMed ID: 37105713
[TBL] [Abstract][Full Text] [Related]
27. A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder.
Mahableshwarkar AR; Zajecka J; Jacobson W; Chen Y; Keefe RS
Neuropsychopharmacology; 2015 Jul; 40(8):2025-37. PubMed ID: 25687662
[TBL] [Abstract][Full Text] [Related]
28. Vortioxetine improves symptomatic and functional outcomes in major depressive disorder: A novel dual outcome measure in depressive disorders.
Christensen MC; Loft H; McIntyre RS
J Affect Disord; 2018 Feb; 227():787-794. PubMed ID: 29689693
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness of Vortioxetine in Patients with Major Depressive Disorder in Real-World Clinical Practice: French Cohort Results from the Global RELIEVE Study.
Polosan M; Rabbani M; Christensen MC; Simonsen K; Ren H
Neuropsychiatr Dis Treat; 2022; 18():1963-1974. PubMed ID: 36068858
[TBL] [Abstract][Full Text] [Related]
30. Using early changes in cold cognition to predict response to vortioxetine in major depressive disorder.
Park C; Zuckerman H; Subramaniapillai M; Mansur RB; Rosenblat JD; Cao B; Iacobucci M; Lee Y; Levitan R; Blumberger DM; McIntyre RS
Psychiatry Res; 2020 Feb; 284():112767. PubMed ID: 31978627
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness of Vortioxetine in Patients With Major Depressive Disorder in Real-World Clinical Practice: Results of the RELIEVE Study.
Mattingly GW; Ren H; Christensen MC; Katzman MA; Polosan M; Simonsen K; Hammer-Helmich L
Front Psychiatry; 2022; 13():824831. PubMed ID: 35356713
[TBL] [Abstract][Full Text] [Related]
32. A Network Meta-Analysis Comparing Effects of Various Antidepressant Classes on the Digit Symbol Substitution Test (DSST) as a Measure of Cognitive Dysfunction in Patients with Major Depressive Disorder.
Baune BT; Brignone M; Larsen KG
Int J Neuropsychopharmacol; 2018 Feb; 21(2):97-107. PubMed ID: 29053849
[TBL] [Abstract][Full Text] [Related]
33. Which Cognitive Domains are Improved by Treatment with Vortioxetine?
Harrison JE; Lophaven S; Olsen CK
Int J Neuropsychopharmacol; 2016 May; 19(10):. PubMed ID: 27231256
[TBL] [Abstract][Full Text] [Related]
34. A Taiwanese study on real-world evidence with vortioxetine in patients with major depression in Asia (TREVIDA).
Yang YK; Chen CS; Tsai CF; Chang CM; Lai TJ; Lee CT; Lin CC; Lan TH; Herr KJ
Curr Med Res Opin; 2021 Dec; 37(12):2163-2173. PubMed ID: 34515596
[TBL] [Abstract][Full Text] [Related]
35. Results of a real-world study on vortioxetine in patients with major depressive disorder in South East Asia (REVIDA).
Chin CN; Zain A; Hemrungrojn S; Ung EK; Kwansanit P; Au Yong KC; Chong MSW; Inpa C; Yen TH; Yeoh BBD; Tay LK; Bernardo C; Lim LC; Yap CH; Fones C; Nayak A; Nelleman L
Curr Med Res Opin; 2018 Nov; 34(11):1975-1984. PubMed ID: 29768955
[TBL] [Abstract][Full Text] [Related]
36. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults.
McIntyre RS; Lophaven S; Olsen CK
Int J Neuropsychopharmacol; 2014 Oct; 17(10):1557-67. PubMed ID: 24787143
[TBL] [Abstract][Full Text] [Related]
37. Vortioxetine reduces BOLD signal during performance of the N-back working memory task: a randomised neuroimaging trial in remitted depressed patients and healthy controls.
Smith J; Browning M; Conen S; Smallman R; Buchbjerg J; Larsen KG; Olsen CK; Christensen SR; Dawson GR; Deakin JF; Hawkins P; Morris R; Goodwin G; Harmer CJ
Mol Psychiatry; 2018 May; 23(5):1127-1133. PubMed ID: 28533517
[TBL] [Abstract][Full Text] [Related]
38. Vortioxetine: a review of its use in major depressive disorder.
Garnock-Jones KP
CNS Drugs; 2014 Sep; 28(9):855-74. PubMed ID: 25145538
[TBL] [Abstract][Full Text] [Related]
39. Vortioxetine for major depressive disorder, vasomotor, and cognitive symptoms associated with the menopausal transition.
Freeman MP; Cheng LJ; Moustafa D; Davies A; Sosinsky AZ; Wang B; Petrillo LF; Hogan C; Cohen LS
Ann Clin Psychiatry; 2017 Nov; 29(4):249-257. PubMed ID: 29069110
[TBL] [Abstract][Full Text] [Related]
40. A 6-Month Open-Label Study of Vortioxetine among Cancer Patients with Major Depressive Disorder (MDD).
Ng CG; Abousheishaa AA; Low SY; Zainal NZ; Thong KS; Awaluddin AB; Loo TH; Yacob SB; Nik Jaafar NR; Abdul Taib NIA; Mohamad Kamal NAB; Ismail F; Zamaniah Wi W
Asian Pac J Cancer Prev; 2023 Aug; 24(8):2583-2591. PubMed ID: 37642043
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
